25 citations
,
November 2013 in “Journal of the American Academy of Dermatology” This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.
19 citations
,
April 2016 in “Case Reports in Dermatology” This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.
16 citations
,
March 2013 in “JAMA Dermatology” This case study describes a 33-year-old woman with chronic myelogenous leukemia who developed nonscarring alopecia after starting nilotinib therapy, linked to perifollicular inflammation.
10 citations
,
August 2016 in “Dermatology Online Journal” This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.
5 citations
,
January 2021 in “Indian Journal of Pharmacology” This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.
April 2025 in “Turkish Journal of Hematology” Nilotinib may cause gray hair to return to its original color.
April 2023 in “Journal of Investigative Dermatology” This study found that while nicotinic acid significantly inhibited human sebaceous organoid growth in vitro, the predicted skin concentrations from gut microbiome-derived levels were far below the effective dose, suggesting high oral doses would be necessary for therapeutic effects.
April 2018 in “Journal of Investigative Dermatology” The researchers reported that nicotinic acid normalized excessive sebaceous lipogenesis without affecting basal lipogenesis and suggested potential anti-acne benefits.
August 2013 in “Hospital Pharmacy” This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.
32 citations
,
September 2015 in “Dermatology” This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.
December 2023 in “Journal of clinical medicine” This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.
22 citations
,
August 1940 in “The journal of investigative dermatology/Journal of investigative dermatology” This review discusses the historical understanding of nutritional dermatoses related to Vitamin B complex deficiencies and reports no new experimental results.
15 citations
,
June 2018 in “Life Sciences” This study found that Diabetex significantly improved wound healing and reduced fasting blood sugar in diabetic rats, showing potential as a safe and economic treatment strategy for diabetic-resistant wounds.
4 citations
,
April 2008 in “Experimental Dermatology” This review hypothesizes that nicotine plays a crucial role in the pathogenesis of hidradenitis suppurativa by promoting inflammation and microbial growth, suggesting that anticholinergic agents might be a potential treatment strategy, but reports no new clinical findings.
1 citations
,
June 2006 in “Experimental dermatology” In this study, researchers identified similar presence of various nicotinic and muscarinic AChRs in lesional and normal epidermis, suggesting that tobacco-delivered nicotine may exacerbate acne inversa by interacting with endogenously produced acetylcholine.
December 2020 in “Zenodo (CERN European Organization for Nuclear Research)” This article discusses three herbal plants commonly used for hair growth support and reports no new clinical results; the authors suggest these herbs may help restore hair health.
April 2016 in “Journal of Investigative Dermatology” This study found that the peptide derivative beta-Ala-Pro-Dab-NHbenzyl may reduce wrinkles and sebum production in human skin by inhibiting dipeptidyl peptidase 4, suggesting potential for acne and skin inflammation treatment.
74 citations
,
March 1963 in “Archives of Dermatology” This article reviews historical reports of skin changes, such as pseudoacanthosis nigricans, associated with cholesterol-lowering drugs like triparanol and nicotinic acid, but presents no new clinical findings.
This study identified several compounds, including Pictilisib and Nimorazole, that may have higher binding affinity for SARS-CoV-2 main protease than existing inhibitors, potentially offering new treatment alternatives for Covid-19.
508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
1 citations
,
December 2025 in “PLoS ONE” This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.
5 citations
,
January 2024 in “Journal of Cancer” In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.
June 2024 in “ESMO Gastrointestinal Oncology” The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.
December 2025 in “Drug Design Development and Therapy” This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.
25 citations
,
January 2011 in “Annals of Dermatology” This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.
December 2022 in “International Journal of Molecular Sciences” This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.
8 citations
,
December 2007 in “Journal of Thoracic Oncology” Erlotinib can cause significant but temporary hair loss in lung cancer patients.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
June 2019 in “International journal of dermatology and venereology” This case report highlights a 73-year-old man developing rosacea-like dermatitis after taking icotinib hydrochloride for NSCLC, suggesting awareness of this side effect is important for clinicians.
44 citations
,
April 2006 in “Expert opinion on drug safety” This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.